Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 for tumor-biological risk assessment in node-negative breast cancer patients – The multicenter trial NNBC 3-Europe
C. Thomssen, M. Vetter, D. Paepke, M. Schmidt, C. Veyret, D. Augustin, V. Hanf, P. Martin, G. von Minckwitz, N. HarbeckVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)70783-3
File:
PDF, 75 KB
english, 2008